MaineCare Services
An Office of the Department of Health and Human Services
Paul R. LePage, Governor Mary C. Mayhew, Commissioner

Department of Health and Human Services
MaineCare Services
11 State House Station
Augusta, Maine 04333-0011
Tel.: (207) 287-2674; Fax: (207) 287-2675
TTY Users: Dial 711 (Maine Relay)

DUR COMMITTEE AGENDA

Date: Tuesday, December 13, 2016
Time: 5:30PM to 8:30PM
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

1) Call to Order

2) Introductions of New Committee Members

3) MaineCare Updates

4) Public Comments

5) Old Business

   - Review of Minutes

6) Closed Session

   - Drug Financial Information Review

7) New Business (open session)

   A. PCM Report- Hepatis C

   B. Use of Antipsychotics in Maine Report

   C. Retro-DUR

      - Introduce: Co-prescribing of stimulants, benzodiazepines and “Z” drugs.

   D. New Drug Review
      Bromsite
      Byvalson
      Emverm
      Exondys
      Inflectra
      Invokamet XR
      Jentadeuto XR
      Onzetra
      Otovel
      Probuphine
      Qbrelis
      Relistor Tabs
      Sustol Inj
      Zurampic

E. FDA Safety Alerts

FDA analyses conclude that Xarelto clinical trial results were not affected by faulty monitoring device
http://www.fda.gov/Drugs/DrugSafety/ucm524678.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement - Risks Associated With Abuse and Dependence
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm526151.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA launches competition to spur innovative technologies to help reduce opioid overdose deaths
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm520945.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Eye Wash/Eye Irrigating Solutions Distributed by Major Pharmaceuticals and Rugby Laboratories: Recall - Microbial Contamination
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519570.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Hyoscyamine Sulfate 0.125mg by Virtus Pharmaceuticals: Recall - Superpotent and Subpotent Test Results
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm520868.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518486.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring Boxed Warning About Serious Risks and Death
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518710.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Ovarian Cancer Screening Tests: Safety Communication - FDA Recommends Against Use
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519540htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm523690.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

F. Next Meeting (Tuesday, March 14th , 2017 from 5:30pm to 8:30pm)

G. Adjournment: 8:30PM